Molecular modelling of CYP3A4 from an alignment with CYP102: Identification of key interactions between putative active site residues and CYP3A-specific chemicals

References

• Andersson T., Miners J. O., Veronse M. E., Tassaneeyakul W., Meyer U. A., Birkett D. J. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. British Journal of Clinical Pharmacology 1993; 36: 521–530
   PubMed Web of Science ®Google Scholar
• Beaune P. H., Umbenhauer D. R., Bork R. W., Lloyd R. S., Guengerich F. P. Isolation and sequence determination of a cNDA clone related to human cytochrome P-450 nifedipine oxidase. Proceedings of the National Academy of Sciences, USA 1986; 83: 8064–8068
   PubMed Web of Science ®Google Scholar
• Bloomer J. C., Baldwin S. J., Smith G. J., Ayrton A. D., Clarke S. E., Chenery R. J. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. British Journal of Clinical Pharmacology 1994; 38: 557–566
   PubMed Web of Science ®Google Scholar
• Bork R. W., Muto T., Beaune P. H., Srivastava P. K., Lloyd R. S., Guengerich F. P. Characterisation of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. Journal of Biological Chemistry 1989; 264: 910–919
   PubMed Web of Science ®Google Scholar
• Degtyarenko K. N., Archakov A. I. Molecular evolution of P450 superfamily and P450-containing monoxygenase systems. FEBS Letters 1993; 332: 1–8
   PubMed Web of Science ®Google Scholar
• De Lemos-Chiarandini C., Frey A. B., Sabatinini D. D., Kreibich G. Determination of the membrane topology of the phenobarbital-inducible rat liver cytochrome P-450 isoenzyme PB-4 using site-specific antibodies. Journal of Cell Biology 1987; 104: 209–219
   PubMed Web of Science ®Google Scholar
• Eaton D. L., Gallagher E. P. Mechanisms of aflatoxin carcinogenesis. Annual Review of Pharmacology and Toxicology 1994; 34: 135–172
   PubMed Web of Science ®Google Scholar
• Ferenczy G. G., Morris G. M. The active site of cytochrome P-450 nifedipine oxidase: a model-building study. Journal of Molecular Graphics 1989; 7: 206–211
   PubMedGoogle Scholar
• Fischer V., Vickers A. E. M., Heitz F., Mahadevan S., Baldeck J. P., Minery P., Tynes R. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metabolism and Disposition 1994; 22: 269–274
   PubMed Web of Science ®Google Scholar
• Gonzalez F. J. Human cytochromes P450: problems and prospects. Trends in Pharmaceutical Sciences 1992; 13: 346–352
   PubMed Web of Science ®Google Scholar
• Gonzalez F. J., Gelboin H. V. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metabolism Reviews 1994; 26: 165–183
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. Toxicology Letters 1994; 70: 133–138
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chemical Research in Toxicology 1991; 4: 391–407
   PubMed Web of Science ®Google Scholar
• Guengerich F. P., Shimada T., Raney K. D., Yun C.-H., Meyer D. J., Ketterer B., Harris T. M., Groopman J. D., Kadlubar F. F. Elucidation of catalytic specificities of human cytochrome P450 and glutathione S-transferase enzymes and relevance to molecular epidemiology. Environmental Health Perspectives 1992; 98: 75–80
   PubMedGoogle Scholar
• Halpert J. R., Guengerich F. P., Bend J. R., Correia M. A. Selective inhibitors of cytochromes P450. Toxicology and Applied Pharmacology 1994; 125: 163–175
   PubMed Web of Science ®Google Scholar
• Hasemann C. A., Kurumbail R. G., Boddupalli S. S., Peterson J. A., Deisenhofer J. Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure 1995; 3: 41–62
   PubMed Web of Science ®Google Scholar
• Hunt C. M., Watkins P. B., Saenger P., Stave G. M., Barlascini N., Watlington C. O., Wright J. T., Guzelian P. S. Heterogeneity of CYP3A isoforms metabolising erythromycin and cortisol. Clinical Pharmacology and Therapeutics 1992; 51: 18–23
   PubMed Web of Science ®Google Scholar
• Jacolot F., Simon I., Dreano Y., Beaune P., Riche C., Berthou F. Identification of the cytochrome P450IIIA family and the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochemical Pharmacology 1911; 41, 1919
   Google Scholar
• Koley A. P., Buters J. T. M., Robinson R. C., Markowitz A., Friedman F. K. CO binding kinetics of human cytochrome P450 3A4. Journal of Biological Chemistry 1995; 270: 5014–5018
   PubMed Web of Science ®Google Scholar
• Korzekwa K. R., Jones J. P. Predicting the cytochrome P450 mediated metabolism of xenobiotics. Pharmacogenetics 1993; 3: 1–18
   PubMedGoogle Scholar
• Kronbach T., Fischer V., Meyer U. A. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolising enzyme explains interactions of cyclosporine with other drugs. Clinical Pharmacology and Therapeutics 1988; 43: 630–635
   PubMed Web of Science ®Google Scholar
• Lake B. G., Lewis D. F. V. The CYP4 family. Cytochromes P450 : Metabolic and Toxicological Aspects, C. Ioannides. CRC Press, Boca Raton 1996; 269–295
   Google Scholar
• Leeder J. S., Gaedigk A., Lu X., Cook V. A. (1994) Characterisation of the human anti-cytochrome P450 antibody response in hypersensitivity reactions to aromatic anticonvulsants. Proceedings of the 10th International Symposium on Microsomes and Drug Oxidations, TorontoCanada, July, 18–211994, 161–163
   Google Scholar
• Lewis D. F. V. Three-dimensional models of human and other mammalian microsomal P450s constructed from an alignment with P450102 (P450bm3). Xenobiotica 1995; 25: 333–366
   PubMed Web of Science ®Google Scholar
• Lewis D. F. V. Cytochromes P450 : Structure, Function and Mechanism. Taylor & Francis, London 1996a
   Google Scholar
• Lewis D. F. V. Molecular modelling of mammalian cytochromes P450 with specific substrates and inhibitors. Cytochromes P450 : Metabolic and Toxicological Aspects, C. Ioannides. CRC Press, Boca Raton 1996b; 353–389
   Google Scholar
• Lewis D. F. V., Lake B. G. Molecular modelling of members of the P4502A subfamily: application to studies of enzyme specificity. Xenobiotica 1995; 25: 585–598
   PubMed Web of Science ®Google Scholar
• Lewis D. F. V., Lake B. G., Parke D. V. Molecular orbital-generated QSARs in an homologous series of alkoxyresorufins and studies of their interative docking with cytochromes P450. Xenobiotica 1995; 25: 1355–1369
   PubMed Web of Science ®Google Scholar
• Lewis D. F. V., Moereels H., Lake B. G., Ioannides C., Parke D. V. Molecular modelling of enzymes and receptors involved in carcinogenesis: QSARs and Compact-3D. Drug Metabolism Reviews 1994; 26: 261–285
   PubMed Web of Science ®Google Scholar
• Lindberg R. L. P., Negishi M. Alteration of mouse cytochrome P450 substrate specificity by mutation of single amino-acid residue. Nature 1989; 339: 632–634
   PubMed Web of Science ®Google Scholar
• Maenpaa J., Pelkonen O., Cresteil T., Rane A. The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. Journal of Steroid Biochemistry and Molecular Biology 1993; 44: 61–67
   PubMed Web of Science ®Google Scholar
• Manchee G. R., Eddershaw P. J., Ranshaw L. E., Herriott D., Park G. R., Bayliss M. K., Tarbit M. H. The aliphatic oxidation of salmeterol to α-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A. Drug Metabolism and Disposition 1996; 24: 555–559
   PubMed Web of Science ®Google Scholar
• Mueller E. J., Loida P. J., Sligar S. G. Twenty-five years of P450cam research. Cytochrome P450, P. R. Ortiz de Montellano. Plenum, New York 1995; 83–124
   Google Scholar
• Nelson D. R., Kamataki T., Waxman D. J., Guengerich F. P., Estabrook R. W., Feyereisen R., Gonzalez F. J., Coon M. J., Gunsalus I. C., Gotoh O., Okuda K., Nebert D. W. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names and nomenclature. DNA and Cell Biology 1993; 12: 1–51
   PubMed Web of Science ®Google Scholar
• Nelson D. R., Koymans L., Kamataki T., Stegeman J. J., Feyereisen R., Waxman D. J., Waterman M. R., Gotoh O., Coon M. J., Estabrook R. W., Gunsalus I. C., Nebert D. W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1–42
   PubMedGoogle Scholar
• Paulsen M. D., Ornstein R. L. Dramatic differences in the motions of the mouth of open and closed cytochrome P450BM-3 by molecular dynamics simulations. Proteins : Structure, Function and Genetics 1995; 21: 237–243
   PubMedGoogle Scholar
• Poulos T. L. Cytochrome P450: molecular architecture, mechanism, and prospects for rational inhibitor design. Pharmaceutical Research 1988; 5: 67–75
   PubMed Web of Science ®Google Scholar
• Poulos T. L. Ligands and electrons and haem proteins. Nature and Structural Biology 1996; 3: 401–403
   PubMedGoogle Scholar
• Poulos T. L., Howard A. J. Crystal structures of metyrapone- and phenylimidazole-inhibited complexes of cytochrome P-450cam. Biochemistry 1987; 26: 8165–8174
   PubMed Web of Science ®Google Scholar
• Poulos T. L., Raag R. Cytochrome P450cam: crystallography, oxygen activation, and electron transfer. FASEB Journal 1992; 6: 674–679
   PubMed Web of Science ®Google Scholar
• Raag R., Poulos T. L. Crystal structure of the carbon monoxide-substrate-cytochrome P-450cam ternary complex. Biochemistry 1989; 28: 7586–7592
   PubMed Web of Science ®Google Scholar
• Ravichandran K. G., Boddupalli S. S., Haseman C. A., Peterson J. A., Deisenhofer J. Crystal structure of hemoprotein domain of P450 BM-3, a prototype for microsomal P450s. Science 1993; 261: 731–736
   PubMed Web of Science ®Google Scholar
• Shimada T., Zamazaki H., Mimura M., Inui Y., Guengerich F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals. Journal of Pharmacology and Experimental Therapeutics 1994; 270: 414–423
   PubMed Web of Science ®Google Scholar
• Shou M., Grogan J., Mancewicz J. A., Krausz K. W., Gonzalez F. J., Gelboin H. V., Korzekwa K. R. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 1994; 33: 6450–6455
   PubMed Web of Science ®Google Scholar
• Smith D. A. Species differences in metabolism and pharmacokinetics: are we close to an understanding?. Drug Metabolism Reviews 1991; 23: 355–373
   PubMed Web of Science ®Google Scholar
• Smith D. A., Jones B. C. Speculations on the substrate structure—activity relationship (SSAR) of cytochrome P450 enzymes. Biochemical Pharmacology 1992; 44: 2089–2098
   PubMed Web of Science ®Google Scholar
• Spatzenegger M., Jaegger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metabolism Reviews 1995; 27: 397–417
   PubMed Web of Science ®Google Scholar
• Tuck S. F., Graham-Lorence S., Peterson J. A., Ortiz De Montellano P. R. Active sites of the cytochrome P450cam (CYP101) F87W and F87A mutants. Journal of Biological Chemistry 1993; 268: 269–275
   PubMedGoogle Scholar
• Von Wachenfeldt C., Johnson E. F. Structures of eukaryotic cytochrome P450 enzymes. Cytochrome P450, P. R. Ortiz de Montellano. Plenum, New York 1995; 183–223
   Google Scholar
• Watkins P. B. Role of cytochromes P450 in drug metabolism and hepatotoxicity. Seminars in Liver Disease 1990; 10: 235–250
   PubMed Web of Science ®Google Scholar
• Waxman D. J., Lapenson D. P., Aoyama T., Gelboin H. V., Gonzalez F. J., Korzekwa K. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Archives of Biochemistry and Biophysics 1991; 290: 160–166
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., Stevens J. C. The human hepatic cytochromes P450 involved in drug metabolism. Critical Reviews in Toxicology 1992; 22: 1–21
   PubMed Web of Science ®Google Scholar